Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.

Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.

Abstract: This invention relates to a process for preparing a tart cherry extract composition by combining a tart cherry extract with a rosmarinic acid extract. Related compositions and methods are also provided.

Abstract: The invention relates to a process for preparing an elderberry extract composition. The invention also relates to an elderberry extract composition obtainable by the aforementioned process and nutraceutical and pharmaceutical compositions comprising said extract composition.

Abstract: The invention provides a fenugreek extract composition containing at least one of diosgenin, gitogenin, sarsasapogenin, dioscin, protodioscin, pseudoprotodioscin, apigenin or a derivative thereof, luteolin or a derivative thereof, nicotinic acid or a derivative thereof, and kaempferol, or a salt or solvate of any one thereof. Also provided are processes of preparing the extract composition, and nutraceutical and pharmaceutical compositions containing the extract composition.

Abstract: Provided is a Withania somnifera extract composition contains at least one of withaferin A, withanoside IV, withanoside V, withanoside VI, withanolide A, withanolide B, anaferine, anahygrine, 12-deoxywithastromonolide, sitoindoside X, sitoindoside IX, cuscohygrine, isopelletierine, bracteosin A, bracteosin B, or bracteosin C, or a salt or solvate of any one thereof. Related compositions, methods, and processes are also provided.

Abstract: Disclosed herein is method for increasing vitamin B12 levels in a subject comprising administering to the subject a composition comprising: at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1). In certain embodiments, the UF1 is probiotic. In certain implementations, the administration of the composition increases the subject's serum B12 levels by at least about 10% relative to the subject's serum B12 level prior to administration of the composition. In further embodiments, the administration of the composition confers at least on benefit on the subject selected from; an increase in serum levels of at least one of vitamin B2, B5, B6, B9, and/or B12; an increase in at least one of tryptophan, tyrosine, phenylalanine; increased propionic acid, immune system modulation and/or augmentation, regulation of TH17 cells; and/or reduction in pro-inflammatory metabolites.

Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.

Abstract: The invention relates to pharmaceutical compositions comprising dopamine transporter inhibitors and to their use in the prophylaxis or treatment of disease states or conditions mediated by the dopamine transporter.